Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “neutral” rating reiterated by investment analysts at Goldman Sachs in a note issued to investors on Tuesday. They currently have a GBX 1,070 ($18.21) target price on the stock. Goldman Sachs’ target price would suggest a potential upside of 2.39% from the stock’s previous close.

Shares of Smith & Nephew plc (LON:SN) traded down 1.32% during mid-day trading on Tuesday, hitting GBX 1045.00. 2,178,090 shares of the company’s stock traded hands. Smith & Nephew plc has a 1-year low of GBX 720.00 and a 1-year high of GBX 1136.00. The stock’s 50-day moving average is GBX 999.7 and its 200-day moving average is GBX 923.4. The company’s market cap is £9.332 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Wednesday, June 18th. They now have a GBX 1,160 ($19.74) price target on the stock. Separately, analysts at BNP Paribas reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Monday, June 16th. They now have a GBX 1,000 ($17.02) price target on the stock. Finally, analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Wednesday, June 11th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of GBX 944 ($16.07).

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.